Literature DB >> 11076532

The conserved cysteine 7.38 residue is differentially accessible in the binding-site crevices of the mu, delta, and kappa opioid receptors.

W Xu1, C Chen, P Huang, J Li, J K de Riel, J A Javitch, L Y Liu-Chen.   

Abstract

Binding pockets of the opioid receptors are presumably formed among the transmembrane domains (TMDs) and are accessible from the extracellular medium. In this study, we determined the sensitivity of binding of [(3)H]diprenorphine, an antagonist, to mu, delta, and kappa opioid receptors to charged methanethiosulfonate (MTS) derivatives and identified the cysteine residues within the TMDs that conferred the sensitivity. Incubation of the mu opioid receptor expressed in HEK293 cells with MTS ethylammonium (MTSEA), MTS ethyltrimethylammonium (MTSET), or MTS ethylsulfonate (MTSES) inhibited [(3)H]diprenorphine binding with the potency order of MTSEA > MTSET > MTSES. Pretreatment of mu, delta, and kappa opioid receptors with MTSEA dose-dependently inhibited [(3)H]diprenorphine binding with MTSEA sensitivity in the order of kappa > mu >> delta. The effects of MTSEA occurred rapidly, reaching the maximal inhibition in 10 min. (-)-Naloxone, but not (+)-naloxone, prevented the MTSEA effect, demonstrating that the reaction occurs within or in the vicinity of the binding pockets. Each cysteine residue in the TMDs of the three receptors was mutated singly, and the effects of MTSEA treatment were examined. The mutants had similar affinities for [(3)H]diprenorphine, and C7. 38(321)S, C7.38(303)S, and C7.38(315)S mutations rendered mu, delta, and kappa opioid receptors less sensitive to the effect of MTSEA, respectively. These results indicate that the conserved Cys7.38 is differentially accessible in the binding-site crevice of these receptors. The second extracellular loop of the kappa receptor, which contains several acidic residues, appears to play a role, albeit small, in its higher sensitivity to MTSEA, whereas the negative charge of Glu6.58(297) did not. To the best of our knowledge, this is the first report to show that a conserved residue among highly homologous G protein-coupled receptors is differentially accessible in the binding-site crevice. In addition, this represents the first successful generation of MTSEA-insensitive mutants of mu, delta, and kappa opioid receptors, which will allow determination of residues accessible in the binding-site crevices of these receptors by the substituted cysteine accessibility method.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11076532     DOI: 10.1021/bi001099p

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  11 in total

Review 1.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

2.  Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptor.

Authors:  Feng Yan; Ruslan V Bikbulatov; Viorel Mocanu; Nedyalka Dicheva; Carol E Parker; William C Wetsel; Philip D Mosier; Richard B Westkaemper; John A Allen; Jordan K Zjawiony; Bryan L Roth
Journal:  Biochemistry       Date:  2009-07-28       Impact factor: 3.162

3.  The seventh transmembrane domains of the delta and kappa opioid receptors have different accessibility patterns and interhelical interactions.

Authors:  Wei Xu; Mercedes Campillo; Leonardo Pardo; J Kim de Riel; Lee-Yuan Liu-Chen
Journal:  Biochemistry       Date:  2005-12-13       Impact factor: 3.162

4.  Intrinsic relative activities of κ opioid agonists in activating Gα proteins and internalizing receptor: Differences between human and mouse receptors.

Authors:  Kelly M DiMattio; Frederick J Ehlert; Lee-Yuan Liu-Chen
Journal:  Eur J Pharmacol       Date:  2015-06-06       Impact factor: 4.432

5.  The role of the hydrophilic Asn230 residue of the mu-opioid receptor in the potency of various opioid agonists.

Authors:  J Pil; J Tytgat
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

6.  K303⁶·⁵⁸ in the μ opioid (MOP) receptor is important in conferring selectivity for covalent binding of β-funaltrexamine (β-FNA).

Authors:  Kelly M DiMattio; Chongguang Chen; Lei Shi; Lee-Yuan Liu-Chen
Journal:  Eur J Pharmacol       Date:  2014-12-04       Impact factor: 4.432

7.  Agonist-promoted Lys63-linked polyubiquitination of the human kappa-opioid receptor is involved in receptor down-regulation.

Authors:  Jian-Guo Li; Dale S Haines; Lee-Yuan Liu-Chen
Journal:  Mol Pharmacol       Date:  2008-01-22       Impact factor: 4.436

8.  Modeling and simulation of the human delta opioid receptor.

Authors:  Mahalaxmi Aburi; Paul E Smith
Journal:  Protein Sci       Date:  2004-07-06       Impact factor: 6.725

9.  14-3-3ζ Protein regulates anterograde transport of the human κ-opioid receptor (hKOPR).

Authors:  Jian-Guo Li; Chongguang Chen; Peng Huang; Yujun Wang; Lee-Yuan Liu-Chen
Journal:  J Biol Chem       Date:  2012-09-18       Impact factor: 5.157

10.  Differential modulation of mu- and delta-opioid receptor agonists by endogenous RGS4 protein in SH-SY5Y cells.

Authors:  Qin Wang; Lee-Yuan Liu-Chen; John R Traynor
Journal:  J Biol Chem       Date:  2009-05-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.